We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
N-of-One to Provide Clinical Interpretation for Guardant360™ Tests
Product News

N-of-One to Provide Clinical Interpretation for Guardant360™ Tests

N-of-One to Provide Clinical Interpretation for Guardant360™ Tests
Product News

N-of-One to Provide Clinical Interpretation for Guardant360™ Tests


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "N-of-One to Provide Clinical Interpretation for Guardant360™ Tests"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

N-of-One today announced an agreement with Guardant Health to provide clinical decision support for Guardant360™, a breakthrough blood test that enables next generation sequencing of solid tumor DNA. Financial terms of the agreement are not disclosed.

Guardant360 is the first pan-cancer blood test that helps oncologists prescribe the right treatments at the right time based on the changing genomics of a patient's cancer. The test uses trace fragments of tumor DNA that are shed into the bloodstream ("cell-free DNA") for reconstructing and sequencing a patient’s cancer to detect emergent alterations that can help oncologists better match patients to potential therapeutic options.

N-of-One’s clinical interpretation provides relevant biological and clinical knowledge related to the mutation profile of the identified tumor DNA, and links this state-of-the-art knowledge to relevant therapeutic strategies, including clinical trials, to support oncologists in making molecularly-informed, personalized treatment decisions.

"Guardant360 is the first comprehensive, non-invasive tumor sequencing test providing real-time answers," said Helmy Eltoukhy, Ph.D., Guardant Health's co-founder and chief executive officer. “Knowledge of genomic alterations in combination with potential therapies can be most helpful to an oncologist and the treatment of their patients."

“N-of-One provides diagnostic companies with best in class, state-of-the-art biological and clinical knowledge relevant to each test’s findings” said Chris Cournoyer, CEO of N-of-One. “Leveraging N-of-One clinical knowledge enables diagnostic companies to scale their test volumes in a cost effective manner.”

Advertisement